Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03999411 · ClinicalTrials.gov registry record · Phase 4
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
A Phase 4 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
NCT03999411: Completed Phase 4 study, sponsored by University of Miami.
NCT03999411 is a Phase 4 study that has completed, run by University of Miami. The registered enrollment target is 39 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03999411, a Phase 4 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if a mindfulness-based smoking cessation smartphone app can help people quit smoking and stay on antiretroviral therapies.
Primary Outcome
Participants who self-report seven days of non-smoking.
Interventions
- DRUG Nicoderm C-Q Transdermal Product
- BEHAVIORAL Adherence to Antiretroviral Therapy Counseling
- BEHAVIORAL Behavioral Smoking Cessation Counseling
- BEHAVIORAL "Crave-to-Quit" app
- BEHAVIORAL vDOT "emocha" app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2020-10-14 |
| Phase | Phase 4 |
What the finished NCT03999411 record still lists
NCT03999411 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 5 interventions - of which Nicoderm C-Q Transdermal Product is the first listed.
NCT03999411 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03999411 about?
NCT03999411 is a clinical study titled "Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients". The purpose of this study is to learn if a mindfulness-based smoking cessation smartphone app can help people quit smoking and stay on antiretroviral therapies.
What is the current status of trial NCT03999411?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2019-09-09. Estimated completion is 2020-10-14.
What interventions are being tested in trial NCT03999411?
The interventions under investigation include: Nicoderm C-Q Transdermal Product (DRUG), Adherence to Antiretroviral Therapy Counseling (BEHAVIORAL), Behavioral Smoking Cessation Counseling (BEHAVIORAL), "Crave-to-Quit" app (BEHAVIORAL), vDOT "emocha" app (BEHAVIORAL).
Who is sponsoring clinical trial NCT03999411?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03999411's enrollment target sits among peer trials
39 1468th of 2000 higher than 525 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI